Follicle-Stimulating Hormone, Its Association with Cardiometabolic Risk Factors, and 10-Year Risk of Cardiovascular Disease in Postmenopausal Women.
Follicle-Stimulating Hormone, Its Association with Cardiometabolic Risk Factors, and 10-Year Risk of Cardiovascular Disease in Postmenopausal Women.
复制标题
卵泡刺激激素、其与心脏代谢危险因素的关系以及绝经后妇女 10 年心血管疾病的风险。
DOI：
10.1161/jaha.117.005918
复制
发表时间：
2017-08-30
影响因子：
5.4
通讯作者：
Lu Y
中科院分区：
文献类型：
--
作者：
Wang N;Shao H;Chen Y;Xia F;Chi C;Li Q;Han B;Teng Y;Lu Y
心血管疾病是绝经后妇女死亡的主要原因。卵泡刺激素（FSH）与绝经后妇女的肥胖和糖尿病呈负相关。我们的目的是研究FSH与绝经后女性动脉粥样硬化性心血管疾病（ASCVD）10年风险之间的关系。 SPECT-中国（华东地区代谢性疾病患病率和危险因素调查）是一项在2014-2015年期间进行的22家研究中心、基于人群的研究。这项研究包括2658名绝经后妇女。采用了一种新开发的中国人10年ASCVD风险预测的有效工具。进行回归分析以评估FSH、10年ASCVD风险和多种心脏代谢风险因素之间的关系。随着FSH四分位数的增加，绝经后妇女的平均10年ASCVD风险从4.9%降至3.3%，大多数代谢参数显著改善（所有P趋势<0.05）。在回归分析中，ln-FSH增加1-SD与连续（B-0.12，95%置信区间，-0.16，-0.09，P<0.05）和分类（比值比0.65，95%置信区间，0.49，0.85，P<0.05）10年ASCVD风险呈负相关。这些显著相关性存在于有或无药物使用、肥胖、糖尿病、高血压和血脂异常的亚组中。体重指数和腰围（B均为-0.35，95%置信区间为-0.40，-0.30，P<0.05）在所有代谢指标中的相关性最大，血压的相关性最小。血清FSH水平与绝经后妇女10年ASCVD风险呈负相关。在心脏代谢因素中，肥胖指数与FSH的相关性最大。这些结果表明，低FSH可能是绝经后妇女心血管疾病风险的危险因素或生物标志物。
Cardiovascular disease is the leading cause of mortality in postmenopausal women. Follicle‐stimulating hormone (FSH) shows negative associations with obesity and diabetes mellitus in postmenopausal women. We aimed to study the associations between FSH and 10‐year risk of atherosclerotic cardiovascular disease (ASCVD) in postmenopausal women. SPECT‐China (the Survey on Prevalence in East China for Metabolic Diseases and Risk Factors) is a 22‐site, population‐based study conducted during 2014–2015. This study included 2658 postmenopausal women. A newly developed effective tool for 10‐year ASCVD risk prediction among Chinese was adopted. Regression analyses were performed to assess the relationship among FSH, 10‐year ASCVD risk, and multiple cardiometabolic risk factors. With the increase in FSH quartiles, the mean 10‐year ASCVD risk in postmenopausal women decreased from 4.9% to 3.3%, and most metabolic parameters were significantly ameliorated (all P for trend <0.05). In regression analyses, a 1‐SD increment in ln‐FSH was negatively associated with continuous (B −0.12, 95% confidence interval, −0.16, −0.09, P<0.05) and categorical (odds ratio 0.65, 95% confidence interval, 0.49, 0.85, P<0.05) 10‐year ASCVD risk. These significant associations existed in subgroups with or without medication use, obesity, diabetes mellitus, hypertension, and dyslipidemia. Body mass index and waist circumference (both B −0.35, 95% confidence interval, −0.40, −0.30, P<0.05) had the largest associations of all metabolic measures, and blood pressure had the smallest association. Serum FSH levels were negatively associated with 10‐year ASCVD risk in postmenopausal women. Among cardiometabolic factors, obesity indices had the largest associations with FSH. These results indicated that a low FSH might be a risk factor or a biomarker for cardiovascular disease risk in postmenopausal women.